News FDA approves Keytruda in cervical cancer Merck & Co’s blockbuster Keytruda has been approved in advanced second line cervical cancer, becoming the first drug in its class approved in the indication.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.